Dare Bioscience Inc (DARE.OQ)
DARE.OQ on NASDAQ Stock Exchange Capital Market
1.16USD
23 May 2018
1.16USD
23 May 2018
Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$1.16
$1.16
Open
$1.15
$1.15
Day's High
$1.20
$1.20
Day's Low
$1.15
$1.15
Volume
4,734
4,734
Avg. Vol
158,331
158,331
52-wk High
$12.40
$12.40
52-wk Low
$0.75
$0.75
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.23 | December | 28 May 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 0 | -- | -- | -- |
| (2) OUTPERFORM | 1 | -- | -- | -- |
| (3) HOLD | 0 | -- | -- | -- |
| (4) UNDERPERFORM | 0 | -- | -- | -- |
| (5) SELL | 0 | -- | -- | -- |
| No Opinion | 0 | -- | -- | -- |
| Mean Rating | 2.00 | -- | -- | -- |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-19 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 1 | -0.23 | -0.23 | -0.23 | -- |
| Quarter Ending Sep-18 | 1 | -0.24 | -0.24 | -0.24 | -- |
| Year Ending Dec-18 | 1 | -1.59 | -1.59 | -1.59 | -- |
| Year Ending Dec-19 | 1 | -0.66 | -0.66 | -0.66 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-16 | 5.00 | 0.77 | 4.23 | 84.68 |
| Quarter Ending Sep-16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Jun-16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-16 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Dec-15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | ||||
| Quarter Ending Mar-17 | -3.10 | -2.70 | 0.40 | -12.90 |
| Quarter Ending Dec-16 | -3.35 | -1.60 | 1.75 | -52.24 |
| Quarter Ending Sep-16 | -4.08 | -3.60 | 0.48 | -11.76 |
| Quarter Ending Jun-16 | -4.81 | -4.00 | 0.81 | -16.91 |
| Quarter Ending Mar-16 | -4.26 | -4.90 | 0.64 | -15.10 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 0.00 | 0.00 | -- | -- | -- |
| Quarter Ending Sep-18 | 0.00 | 0.00 | -- | -- | -- |
| Year Ending Dec-18 | 0.00 | 0.00 | -- | -- | -- |
| Year Ending Dec-19 | 0.00 | 0.00 | -- | -- | -- |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -0.23 | -0.23 | -- | -- | -- |
| Quarter Ending Sep-18 | -0.24 | -0.24 | -- | -- | -- |
| Year Ending Dec-18 | -1.59 | -1.59 | -- | -- | -- |
| Year Ending Dec-19 | -0.66 | -0.66 | -- | -- | -- |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | -- | -- |
| Quarter Ending Sep-18 | 0 | 0 | -- | -- |
| Year Ending Dec-18 | 0 | 0 | -- | -- |
| Year Ending Dec-19 | 0 | 0 | -- | -- |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | -- | -- |
| Quarter Ending Sep-18 | 0 | 0 | -- | -- |
| Year Ending Dec-18 | 0 | 0 | -- | -- |
| Year Ending Dec-19 | 0 | 0 | -- | -- |
Earnings vs. 
Estimates- BRIEF-Daré Bioscience Appoints John Fair To Chief Business Officer
- BRIEF-Daré Bioscience Enters Into Agreement To Acquire Product To Address Vulvar And Vaginal Atrophy In Hormone Receptor-Positive Breast Cancer Patients
- BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
- BRIEF-Dare Bioscience Says Board Increased Size To 6 Directors
- BRIEF-Daré Bioscience Says Intends To Communicate With U.S. FDA In Mid-2018 Regarding Phase 2b Study Of Topical Sildenafil